Excellent Response to Anti-PD1 therapy in a Patient with Hepatocellular Carcinoma: Case Report and Review of Literature

Hirva Mamdani(Wayne State University), Amikar Sehdev(Regenstrief Institute), Bert H. O’Neil(Indiana University Health), Howard H. Wu(University of Indianapolis)

IUScholarWorks (Indiana University)

January 1, 2017

Cited by 8

Related Papers

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

|JAMA|2017|891

Immunotherapy in Lung Cancer: Current Landscape and Future Directions

|Frontiers in Immunology|2022|373

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

|Journal of Clinical Oncology|2022|125

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

|Journal of Clinical Oncology|2022|116

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

|UNC Libraries|2020|96